We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biophan Technologies, Inc. (OTCBB: BIPH -- News), a developer of next-generation
biomedical technology, today provided more details on its acquisition of AMRIS,
a German company that designs Magnetic Resonance Imaging (MRI)-compatible stents
and other medical devices, as reported today in The New York Times.
Infinity Pharmaceuticals Inc., an anti-cancer drug-discovery company, has announced
a collaborative deal with a partner to identify new drugs using the company's
collection of compounds.
Nautilus Biotech a protein pharmaceuticals private company and Angel Biotechnology
a UK private company providing world-class contract manufacturing services in
microbial fermentation and mammalian cell culture, announced today that they
have signed an agreement for the manufacture of Nautilus' improved alpha interferon
(Belerofon) for Phase I clinical development.
The FDA issued a proposed rule Jan. 5 to amend the tentative final monograph
(TFM) for OTC drugs that are used to relieve symptoms associated with overindulgence
of food and drink to include new indications for products containing bismuth
subsalicylate.
The biotech market is expected to enjoy a strong 2005 driven by increased collaboration
from large pharmaceutical firms, as well as developing trends in pharmacogenomics
and theranostics, according to a research report published by life sciences
merchant bank Burrill & Company.
Only a handful of the millions of eligible residents have taken advantage of
the country's first state-sponsored prescription drug importation program.
The Canadian government is considering regulations that would restrict the flow
of prescription drugs to American consumers - a potential move that is drawing
fire on both sides of the border.
Nitto Denko and Nitto Denko Technical, a dedicated R&D facility in Oceanside,
Calif., have announced development of a high-performance cross-linked polystyrene
bead which can support a high-grade, high-yield synthesis of oligonucleotides,
essential to DNA and RNA-based gene therapies, and provide solid support for
the synthesis of antisense drugs.
Ligand Pharmaceuticals exercised the first option to buy down a portion of the
royalties payable to Eli Lilly on sales of Ligand's U.S. marketed cancer drug,
Ontak.